A Cautious Note on Thalidomide Usage in Cancer Treatment: Genetic Profiling of the TBX2 Sub-Family Gene Expression is Required
Authors:
- 1 April 2019
- journal article
- research article
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 69 (09) , 512-518
Abstract
Thalidomide is still by excellence the mysterious drug that fascinated, blurred, misled, and changed the scientific community perspectives and policies. It was introduced in the 1950’s as a sedative drug, then shortly withdrawn because of the devastating birth defects that affected tens of thousands throughout more than 40 countries. Back into the market in the mid 1990’s and 2000’s the drug is now being used to treat skin immune-related conditions and some cancers like multiple myeloma. Despite numerous beneficial effects which led to the development of new analogs, its direct mechanisms of action are still elusive. The identification of CRBN and TBX5 as potential direct ligands for this drug have opened the way to better understand its efficiency and its failure.We hereby review these mechanisms and provide evidence that could explain why thalidomide failed to make it as a drug of choice in lung cancer treatment. Linking the genetic signature of TBX2 subfamily in these tumors to their inability to respond properly to thalidomide raises concerns of worsening lung cancer patients’ health if this drug is utilized.Keywords
This publication has 28 references indexed in Scilit:
- Tbx2 Controls Lung Growth by Direct Repression of the Cell Cycle Inhibitor Genes Cdkn1a and Cdkn1bPLOS Genetics, 2013
- Multiple Roles and Interactions of Tbx4 and Tbx5 in Development of the Respiratory SystemPLOS Genetics, 2012
- Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 StudyJournal of Clinical Oncology, 2012
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant DefenseMolecular Pharmaceutics, 2008
- The thalidomide sagaThe International Journal of Biochemistry & Cell Biology, 2007
- Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphateBlood, 2005
- T‐box gene products are required for mesenchymal induction of epithelial branching in the embryonic mouse lungDevelopmental Dynamics, 2002
- Thalidomide and Beyond: Some Recommendations regarding Public Policies toward the Ethical Drug IndustryInternational Journal of Health Services, 1974